Aquila: Hoping for a bull run from cows

By Steve Edelson

Staff Writer Like many small cap biotech companies that have been orphaned by the equity markets, Aquila Biopharmaceuticals Inc. has had to shuffle project priorities and deal with a stock price that does not reflect anything except for its cash. But the company is anticipating a product approval next year that it hopes will allow it to graduate from the ranks of the microcaps into a maturing mid-cap company...